|
(6) Molecular mechanisms explaining premalignant changes in the etiology of melanoma
|
1R21CA208736-01A1
|
$146,000
|
MURPH, MANDI
|
UNIVERSITY OF GEORGIA
|
|
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
|
1R01CA205965-01A1
|
$650,815
|
CURIEL, TYLER
|
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
|
|
(PQ3) The role of damaged DNA in inter-individual variation of tumor immunity
|
5R01CA208756-02
|
$518,165
|
HACOHEN, NIR
|
BROAD INSTITUTE, INC.
|
|
(PQB-4) Opposing Effects of the SASP in Cancer Progression
|
5R01CA184572-04
|
$329,925
|
HERBIG, UTZ
|
RBHS-NEW JERSEY MEDICAL SCHOOL
|
|
(PQD1) Clonal heterogeneity and targeted therapy resistance in melanoma
|
5R01CA185072-04
|
$348,312
|
SEKULIC, ALEKSANDAR
|
MAYO CLINIC ARIZONA
|
|
(PQD1) Evolution of vemurafenib resistance in circulating melanoma cells
|
5R01CA185151-04
|
$613,546
|
NOVINA, CARL
|
DANA-FARBER CANCER INST
|
|
(PQD5) Mass Profiling Melanoma Responses to Improve Therapy Choices and Prognosis
|
5R01CA185189-04
|
$483,693
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
(PQD5) Predicting Anti-Cancer Efficacy through Tumor Profiling
|
5R01CA185353-04
|
$405,890
|
KIM, WILLIAM
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
3D Models of Immunotherapy
|
1U01CA214369-01
|
$574,412
|
MOONEY, DAVID
|
HARVARD UNIVERSITY
|
|
A CD47-blocking oncolytic vaccinia virus for cancer therapy
|
5F30CA203270-02
|
$44,044
|
CAO, FELICIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
A comparison of interventions to teach patients skin self-examination
|
5R01CA154908-07
|
$593,036
|
ROBINSON, JUNE
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
A germline variant that predicts and modulates the response of melanoma to immunotherapy
|
1R21CA209309-01A1
|
$198,103
|
OSMAN, IMAN
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
A High-Throughput Model for Human Melanoma
|
5R01CA121118-09
|
$247,340
|
HOLMEN, SHERI
|
UNIVERSITY OF UTAH
|
|
A NOVEL DRUGGABLE GENETIC VULNERABILITY PATHWAY IN MELANOMA
|
5R01CA200919-02
|
$383,156
|
WAJAPEYEE, NARENDRA
|
YALE UNIVERSITY
|
|
A novel IL-2 biologic and tumor immunity
|
5R21CA195334-02
|
$200,318
|
MALEK, THOMAS
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
A novel in vivo model system of melanoma using a human-mouse neural crest cell chimera
|
5F32CA196065-03
|
$59,166
|
WERT, KATHERINE
|
WHITEHEAD INSTITUTE FOR BIOMEDICAL RES
|
|
A novel NKG2D-specific BiTE cancer immunotherapy
|
5R01CA164178-05
|
$336,150
|
SENTMAN, CHARLES
|
DARTMOUTH COLLEGE
|
|
A novel preclinical model of spontaneous metastasis
|
ZIA BC 011167
|
$524,680
|
Merlino, Glenn
|
CCR (NCI)
|
|
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
|
1R44CA217591-01
|
$621,000
|
KAHN, STUART
|
SYNTRIX BIOSYSTEMS, INC.
|
|
A real-time, cost-effective, accurate UV measurement and sun protection system to prevent and reduce the incidence of sunburn in high-risk consumers.
|
1R44CA224658-01
|
$213,796
|
Meitl, Matthew
|
WEARIFI, INC.
|
|
A research and training program for junior clinicians in treating metastatic mela
|
5K24CA172123-05
|
$156,084
|
KLUGER, HARRIET
|
YALE UNIVERSITY
|
|
A role for AKT2 in BRAFV600E melanoma initiation, progression, and response to therapy
|
5F31CA210312-02
|
$39,784
|
MCREE, SIOBHAN
|
TUFTS UNIVERSITY BOSTON
|
|
A Self-Regulation Approach to an Indoor Tanning Intervention for Frequent Users
|
5K07CA175115-04
|
$137,183
|
STAPLETON, JEROD
|
RBHS -CANCER INSTITUTE OF NEW JERSEY
|
|
Adaptive regulation of cancer cell fate following oncogene inhibition
|
4R00CA194163-03
|
$249,001
|
FALLAHI-SICHANI, MOHAMMAD
|
UNIVERSITY OF MICHIGAN
|
|
Adoptive Cell Therapy with Rejuvenated Antigen-Specific T Cells
|
5K08CA197966-04
|
$174,960
|
ITO, FUMITO
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Adoptive Cell Transfer Immunotherapy of Cancer
|
ZIA BC 010984
|
$1,629,581
|
Rosenberg, Steven
|
CCR (NCI)
|
|
An innate immune checkpoint in cancer immunotherapy
|
1R01CA212376-01A1
|
$455,406
|
ROTHLIN, CARLA
|
YALE UNIVERSITY
|
|
An Internet-Based Behavioral Intervention for Individuals Diagnosed with Melanoma
|
5R01CA171666-04
|
$492,128
|
COUPS, ELLIOT
|
RBHS -CANCER INSTITUTE OF NEW JERSEY
|
|
Animal Model and Genotyping Core Support Facility
|
ZIC BC 011047
|
$814,201
|
DuBois, Wendy
|
CCR (NCI)
|
|
Anti-CD38 targeted alpha emitter radioimmunotherapy to eliminate multiple myeloma
|
1R01CA205248-01A1
|
$697,579
|
GREEN, DAMIAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Antibodies to melanoma vaccine peptides
|
1R03CA219715-01
|
$80,500
|
SLINGLUFF, CRAIG
|
UNIVERSITY OF VIRGINIA
|
|
Assessing the effect of anti-PD-1/PD-L1 agents on tumoricidal efficacy of secretory TRAIL-armed NK cells
|
1R03CA205267-01A1
|
$77,312
|
LEE, YONG
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Augmenting T cell activity to weak tumor antigens and reversing myeloid cell-mediated T cell inhibition
|
1R01CA207913-01A1
|
$363,833
|
DAVILA, EDUARDO
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Automated Image Guidance for Diagnosing Skin Cancer With Confocal Microscopy
|
5R01CA199673-03
|
$619,539
|
RAJADHYAKSHA, MILIND
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Automated Platform for Fixed Tissue Microdissection
|
4R44CA199194-02
|
$747,594
|
KARSTEN, STANISLAV
|
NEUROINDX INC.
|
|
b-catenin in vaccine-induced anti-tumor CD8 T cell immunity
|
5R01CA198105-03
|
$401,456
|
JIANG, AIMIN
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
BACH2 in Melanoma Development and Resistance
|
5K22CA197058-02
|
$177,344
|
KARRETH, FLORIAN
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Beta-adrenergic mediated suppression of T cell chemotaxis by cancers
|
1R03CA216016-01
|
$81,000
|
MULLINS, DAVID
|
DARTMOUTH COLLEGE
|
|
Biomarkers and Resistance Mechanisms in Melanoma T-cell Therapy
|
5R01CA184845-04
|
$337,982
|
HWU, PATRICK
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Biomimetic artificial antigen presenting cells for melanoma immunotherapy
|
5F31CA214147-02
|
$44,044
|
MEYER, RANDALL
|
JOHNS HOPKINS UNIVERSITY
|
|
BLIMP-1 mediated regulation of CD8+ TIL
|
5R01CA166458-05
|
$686,810
|
BULLOCK, TIMOTHY
|
UNIVERSITY OF VIRGINIA
|
|
Blocking an Endogenous Inhibitor of Anti-tumor Leukocyte Recruitment
|
3F32CA200103-02S1
|
$553
|
BRULOIS, KEVIN
|
STANFORD UNIVERSITY
|
|
Blocking an Endogenous Inhibitor of Anti-tumor Leukocyte Recruitment
|
5F32CA200103-03
|
$29,583
|
BRULOIS, KEVIN
|
STANFORD UNIVERSITY
|
|
BRAF splice variants in RAF inhibitor resistant melanoma
|
5F30CA203314-02
|
$45,233
|
VIDO, MICHAEL
|
THOMAS JEFFERSON UNIVERSITY
|
|
Cancer biology in the zebrafish
|
5R01CA103846-15
|
$373,081
|
ZON, LEONARD
|
BOSTON CHILDREN'S HOSPITAL
|
|
Cancer Prevention and Treatment by Activation of a Brain-Adipocyte Axis
|
5R01CA166590-05
|
$319,550
|
CAO, LEI
|
OHIO STATE UNIVERSITY
|
|
Cancer Prevention: Staging my career as a cancer biologist
|
4K00CA212444-02
|
$81,480
|
HAMBRIGHT, HEATHER
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Cancer Risk in Xeroderma Pigmentosum Heterozygotes
|
ZIA CP004410-08065
|
$4,529
|
Goldstein, Alisa
|
DCEG (NCI)
|
|
Case-control study of cutaneous melanoma
|
ZIA CP005803-08070
|
$903
|
Tucker, Margaret
|
DCEG (NCI)
|
|
Cbx-3/HP-1gamma deficiency confers anti-tumor immunity
|
5R21CA198263-02
|
$225,765
|
THAI, TO-HA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|